Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C18H12F6N6O |
|||
Molecular Weight | 442.32 | CAS No. | 1392136-43-4 | |
Solubility (25°C)* | In vitro | DMSO | 88 mg/mL (198.95 mM) | |
Ethanol | 2 mg/mL (4.52 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Verdinexor (KPT-335, ATG-527) is an orally bioavailable, selective XPO1/CRM1 inhibitor. | |
---|---|---|
Targets |
|
|
In vitro | Verdinexor inhibits the viability of Jurkat, OCI-Ly3, OCI-Ly10, and CLBL1 cells with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM, respectively. KPT-335 also induces apoptosis in CLBL1 cells and primary canine DLBCL cells that express XPO1 and SINE. [1] Verdinexor potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain. [2] | |
In vivo | Verdinexor (25 mg/kg twice daily, p.o.) reduces proinflammatory cytokine expression in the lung, produces in vivo antiviral activity by reducing lung virus titers, and thus reduces pulmonary disease pathogenesis and death associated with lethal influenza A virus challenge. [2] In autosomal-dominant polycystic kidney disease model, Verdinexor (5 mg/kg, i.p.) attenuates cyst growth via inhibition of XPO1. [3] |
Cell Assay: |
|
---|---|
Animal Study: |
|
|
Hepatitis B virus virion secretion is a CRM1-spike-mediated late event [ J Biomed Sci, 2022, 29(1):44] | PubMed: 35729569 |
CRM1-spike-mediated nuclear export of hepatitis B virus encapsidated viral RNA [ Cell Rep, 2022, 38(10):110472] | PubMed: 35263598 |
Pancancer transcriptomic profiling identifies key PANoptosis markers as therapeutic targets for oncology [ NAR Cancer, 2022, 4(4):zcac033] | PubMed: 36329783 |
Effects of cadmium on osteoblast cell line: Exportin 1 accumulation, p-JNK activation, DNA damage and cell apoptosis [ Ecotoxicol Environ Saf, 2021, 208:111668] | PubMed: 33396178 |
Expression of HIV-1 Intron-Containing RNA in Microglia Induces Inflammatory Responses [ J Virol, 2020, JVI.01386-20] | PubMed: 33298546 |
A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma [ Cancers (Basel), 2020, 12(11)E3335] | PubMed: 33187254 |
Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets [ Front Oncol, 2020, 10:1424] | PubMed: 32923394 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.